CURATIS N AG (SW:CURN) — Market Cap & Net Worth
Market Cap & Net Worth: CURATIS N AG (CURN)
CURATIS N AG (SW:CURN) has a market capitalization of $89.64 Million (CHF70.90 Million) as of August 1, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #19515 globally and #190 in its home market, demonstrating a -13.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CURATIS N AG's stock price CHF20.40 by its total outstanding shares 5151693 (5.15 Million). See CURN capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
CURATIS N AG Market Cap History: 2015 to 2026
CURATIS N AG's market capitalization history from 2015 to 2026. Data shows change from $1.17 Billion to $132.87 Million (-18.24% CAGR).
CURATIS N AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CURATIS N AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.28x
CURATIS N AG's market cap is 12.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.17 Billion | $15.59 Million | -$1.63 Million | 74.85x | N/A |
| 2016 | $875.36 Million | $17.94 Million | -$1.02 Million | 48.78x | N/A |
| 2017 | $875.36 Million | $17.55 Million | -$260.00K | 49.87x | N/A |
| 2018 | $320.97 Million | $16.19 Million | -$762.00K | 19.82x | N/A |
| 2019 | $496.04 Million | $17.30 Million | -$940.00K | 28.67x | N/A |
| 2020 | $2.36 Billion | $4.11 Million | -$16.00K | 575.20x | N/A |
| 2024 | $84.67 Million | $6.90 Million | -$4.34 Million | 12.28x | N/A |
Competitor Companies of CURN by Market Capitalization
Companies near CURATIS N AG in the global market cap rankings as of August 1, 2026.
Key companies related to CURATIS N AG by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
CURATIS N AG Historical Marketcap From 2015 to 2026
Between 2015 and today, CURATIS N AG's market cap moved from $1.17 Billion to $ 132.87 Million, with a yearly change of -18.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF132.87 Million | +70.00% |
| 2025 | CHF78.16 Million | -7.69% |
| 2024 | CHF84.67 Million | +625.45% |
| 2023 | CHF11.67 Million | -96.49% |
| 2022 | CHF332.64 Million | -85.19% |
| 2021 | CHF2.25 Billion | -4.94% |
| 2020 | CHF2.36 Billion | +376.47% |
| 2019 | CHF496.04 Million | +54.55% |
| 2018 | CHF320.97 Million | -63.33% |
| 2017 | CHF875.36 Million | 0.00% |
| 2016 | CHF875.36 Million | -25.00% |
| 2015 | CHF1.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of CURATIS N AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.64 Million USD |
| MoneyControl | $89.64 Million USD |
| MarketWatch | $89.64 Million USD |
| marketcap.company | $89.64 Million USD |
| Reuters | $89.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more